Tegaserod use in children: a single-center experience.
BACKGROUND
Tegaserod is increasingly prescribed by pediatric gastroenterologists even though there are few published data concerning its use in children. The aim of this study was to describe the authors' experience with tegaserod in children.


METHODS
Patients treated with tegaserod from 2004 through 2006 were included in this study. Defecation and fecal incontinence frequency and global assessment of relief of symptoms were assessed.


RESULTS
Seventy-two patients (44 girls) ranging in age from 1.1 to 18.3 years constitute the patient sample of this report. The median age was 10 years and the median follow-up after initiation of tegaserod treatment was 11.3 months (range 2.3-45.2 months). Indications to prescribe tegaserod were constipation (58%) and a variety of other conditions including functional dyspepsia or inflammatory bowel disease (42%). Defecation frequency increased after tegaserod use (1 vs 7/week, P < 0.001) and presence of fecal incontinence decreased (47% vs 23%, P < 0.001) in the constipation group. Parents rated relief of constipation as moderate or significant in 71% of cases in the constipation group. In the group with other indications to start tegaserod therapy, moderate or significant relief of abdominal pain and bloating was noted in 64% and 68% of patients, respectively. The median dose of tegaserod prescribed was 0.22 mg x kg x day (range 0.05-0.87 mg x kg(-1) x day(-1)). Adverse events were observed in 32% of the patients. The most common side effects were self-limiting diarrhea (20%) and abdominal pain (8%). Only one patient discontinued tegaserod because of side effects; this patient experienced pain at his cecostomy site.


CONCLUSIONS
Tegaserod seems to relieve a variety of functional gastrointestinal symptoms in children. Further randomized controlled studies are needed to support the specific pediatric target of prescribing tegaserod.
Liem
Olivia
O
Department of Pediatric Gastroenterology and Nutrition, Emma Children's Hospital, Academic Medical Center, Amsterdam, The Netherlands. liemo@chi.osu.edu
Mousa
Hayat M
HM
Benninga
Marc A
MA
Di Lorenzo
Carlo
C
D015746:Abdominal Pain / Q000139:chemically induced; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003248:Constipation / Q000188:drug therapy; D003967:Diarrhea / Q000139:chemically induced; D004415:Dyspepsia / Q000188:drug therapy; D005767:Gastrointestinal Diseases / Q000188:drug therapy*; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy; D012189:Retrospective Studies; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*
D007211:Indoles; D017366:Serotonin Receptor Agonists; C105050:tegaserod